The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer

摘要

Study design by Lu et al. PBMCs were isolated from late-stage NSCLC patients and electroporated with plasmids encoding Cas9 and a pair of gRNAs targeting the second exon of PD-1 gene. The edited T cells were expanded in vitro for 17–40 days before being reinfused back into patients. Treated patients were monitored for up to 96 weeks for in vivo persistence of edited T cells, treatment-related AEs, and disease progression